Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.21 USD | -9.52% | -4.37% | +39.64% |
Business Summary
Number of employees: 145
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Small Molecule Drugs
100.0
%
| 86 | 100.0 % | 79 | 100.0 % | -8.07% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 86 | 100.0 % | 79 | 100.0 % | -8.07% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jay Luly
CEO | Chief Executive Officer | 67 | 03-06-30 |
Paul Mellett
DFI | Director of Finance/CFO | 68 | 03-08-31 |
Chief Tech/Sci/R&D Officer | 50 | 22-08-07 | |
Yat Sun Or
CTO | Chief Tech/Sci/R&D Officer | 72 | 99-10-31 |
Jennifer Viera
IRC | Investor Relations Contact | - | 22-12-31 |
Brendan Luu
PRN | Corporate Officer/Principal | 49 | 21-01-25 |
Tara Kieffer
PRN | Corporate Officer/Principal | 46 | 20-12-07 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Foletta
BRD | Director/Board Member | 63 | 20-06-28 |
Lesley Russell
BRD | Director/Board Member | 63 | 16-11-17 |
Bruce Carter
CHM | Chairman | 80 | 13-11-24 |
Jay Luly
CEO | Chief Executive Officer | 67 | 03-06-30 |
Terry Vance
BRD | Director/Board Member | 67 | 11-05-31 |
Yujiro Hata
BRD | Director/Board Member | 49 | 21-08-18 |
Director/Board Member | 64 | 17-09-12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 21,155,983 | 19,865,549 ( 93.90 %) | 0 | 93.90 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.64% | 309M | |
+21.79% | 46.81B | |
-0.85% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.03% | 26.06B | |
-19.04% | 19.13B | |
+32.17% | 12.39B | |
+0.32% | 12.08B | |
+0.32% | 11.96B |
- Stock Market
- Equities
- ENTA Stock
- Company Enanta Pharmaceuticals, Inc.